Salivaomics, Saliva-Exosomics, and Saliva Liquid Biopsy

Jordan Cheng,Taichiro Nonaka,Qianlin Ye,Fang Wei,David T. W. Wong

DOI: https://doi.org/10.1007/978-3-030-35784-9_8

2020-01-01

Abstract:The concept of liquid biopsy has emerged into the cancer lexicon to describe detected alterations of tumor biomarkers within body fluids which reflect the presence and the biology of cancer. This is typically performed by assessing circulating tumor cells (CTCs), circulating tumor DNAs (ctDNAs), tumor-derived extracellular vesicles (EVs), microRNAs (miRNAs), and proteins. Although plasma, urine, and cerebral spinal fluid (CSF) are all viable biofluids, growing attention has recently been cast on saliva. Saliva is readily available, can be obtained noninvasively, is easily collected and stored, and also demonstrates compelling pathophysiological association with systemic diseases. Importantly, saliva liquid biopsy delivers the best clinical performance to detect ctDNAs in lung cancer patients. In conjunction with validated biomarkers, and reliable and robust analytical detection tools, saliva has the potential to pioneer a new landscape of real-time point-of-care testing in personalized medicine. This chapter will review the salivaomics, the disease-related biomarker properties of saliva, and the scientific advances in the pathophysiological foundations which make saliva an ideal candidate for noninvasive liquid biopsy. Moreover, a novel liquid biopsy technology termed electric field-induced release and measurement (EFIRM), which works in tandem with the technological advances to extract crucial disease information in saliva, is reviewed.